GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Shiller PE Ratio

Inotiv (STU:BS50) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Inotiv Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inotiv Shiller PE Ratio Historical Data

The historical data trend for Inotiv's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Shiller PE Ratio Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inotiv Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inotiv's Shiller PE Ratio

For the Diagnostics & Research subindustry, Inotiv's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Inotiv's Shiller PE Ratio falls into.



Inotiv Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Inotiv's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Inotiv's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.711/131.7762*131.7762
=-1.711

Current CPI (Mar. 2024) = 131.7762.

Inotiv Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.015 100.560 0.020
201409 -0.039 100.428 -0.051
201412 0.008 99.070 0.011
201503 -0.009 99.621 -0.012
201506 0.143 100.684 0.187
201509 -0.080 100.392 -0.105
201512 -0.055 99.792 -0.073
201603 -0.027 100.470 -0.035
201606 -0.045 101.688 -0.058
201609 -0.223 101.861 -0.288
201612 0.002 101.863 0.003
201703 0.047 102.862 0.060
201706 0.027 103.349 0.034
201709 0.025 104.136 0.032
201712 0.002 104.011 0.003
201803 0.008 105.290 0.010
201806 -0.009 106.317 -0.011
201809 -0.017 106.507 -0.021
201812 -0.009 105.998 -0.011
201903 -0.053 107.251 -0.065
201906 -0.035 108.070 -0.043
201909 0.027 108.329 0.033
201912 -0.117 108.420 -0.142
202003 -0.045 108.902 -0.054
202006 -0.071 108.767 -0.086
202009 -0.136 109.815 -0.163
202012 -0.025 109.897 -0.030
202103 -0.050 111.754 -0.059
202106 0.141 114.631 0.162
202109 0.051 115.734 0.058
202112 -3.478 117.630 -3.896
202203 -0.218 121.301 -0.237
202206 -0.142 125.017 -0.150
202209 -9.635 125.227 -10.139
202212 -3.219 125.222 -3.387
202303 -0.364 127.348 -0.377
202306 0.065 128.729 0.067
202309 -0.356 129.860 -0.361
202312 -0.550 129.419 -0.560
202403 -1.711 131.776 -1.711

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inotiv  (STU:BS50) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Inotiv Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Inotiv's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (STU:BS50) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines